临床试验工作人员的职责 - nature.doc

SUPPLEMENTARY INFORMATION SUPPLEMENTARY MATERIALS AND METHODS Immunohistochemical analysis We performed immunohistochemistry (IHC) staining as previously described.1, 2 For IHC, antibodies are described in the Supplementary Table S1. Sections immunostained with rabbit or mouse IgG as the primary antibody were used as negative controls. Tissue microarray and evaluation for immunohistochemistry Triplicate cylindrical tissue samples with a diameter of 0.6 mm were punched from representative tumor areas and matching normal mammary gland tissue from surgical specimen tissue blocks. The tissue cylinders were then transferred to the recipient paraffin block at defined array positions by using a tissue-arraying instrument (UNITMA Co., Ltd., Seoul, Korea). The percentage of positively stained was scored using the following scales: 0, no staining of cells in any field; 1, ≤ 10%; 2, 11-50%; 3, 51-75%; 4, 75%. The intensity of staining was scored using the following scales: 1+, weak staining; 2+, moderate staining; 3+, strong staining. Percentage (P) and intensity (I) of nuclear or cytoplasm or membrane expression were multiplied to generate a numerical score (S = P ? I). PTPTO expression levels were assessed as positive or negative, according to the cut-off value 2, which is determined by preliminary data derived from normal breast tissue. This requires counting at least 1000 tumor cells with nuclear staining in ten high-power ?elds (×400). ERBB2 immunoreactivity was scored according to Guidelines for ERBB2 Detection in Breast Cancer, the 2009 version. No staining or membrane staining in 30% of tumor cells. 1+, barely perceptible membrane staining in 30% of tumor cells or cells only stained in part of membrane. 2+, weak/moderate complete membrane staining in 30% of tumor cells. 3+, strong complete membrane staining in 30% of tumor cells. The immunoreactivity was evaluated by two different pathologists with no prior knowledge of patient data. When the opinions of the tw